Pamiparib: First Approval

<p><b>Funding</b> The preparation of this review was not supported by any external funding.</p><p><br></p> <p><b>Authorship and Conflict of interest</b> During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p><p><br></p> <p> </p> <b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability </b>Not applicable.<div><br></div><div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a>.<br></div><div><br></div><div>Abstract</div><div><br></div><div><p>Pamiparib (PARTRUVIX™; BeiGene Ltd.) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor being developed for the treatment of various cancers. Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer previously treated with two or more lines of chemotherapy. This article summarizes the milestones in the development of pamiparib leading to this first approval.</p><p><br></p><p>© Springer Nature Switzerland AG 2021<br></p></div>